Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial to Assess the Safety and Acceptability of the Long-acting Injectable HIV Integrase Inhibitor, Cabotegravir (GSK1265744), in HIV Uninfected Women in KwaZulu-Natal, South Africa

NCT02462772 is registered in ClinicalTrials.gov with Centre for the AIDS Programme of Research in South Africa as lead sponsor.

NCT NCT02462772
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02462772 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial to Assess the Safety and Acceptability of the Long-acting Injectable HIV Integrase Inhibitor, Cabotegravir (GSK1265744), in HIV Uninfected Women in KwaZulu-Natal, South Africa
Lead sponsor
Centre for the AIDS Programme of Research in South Africa
Phase
Phase 2
Overall status
Withdrawn
Start date
October 31, 2015
Completion date
September 30, 2018
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus